Structural characterization and bioimaging of Zn2+ using meta-benziporphodimethene analogue.

'Prevention is better than cure, especially when something has no cure.' Cancer, in most patients is detected at the stage beyond which it becomes noncurative. Therefore, the early detection of cancer cells can play a crucial role in enhancing the chances of a patient's survival. In this light, we present a nonfluorescent receptor used for the detection of Zn2+ ion in MDA-MB-231 carcinoma cells that exhibits fluorescence turn-on behaviour upon binding with the metal ion. In this work, the synthesis of 11,16-bis(2,6-difluorobenzene)-6,6,21,21-tetramethyl-meta-benziporpho-6,21-dimethene and its Zn2+ chloride complex have been reported. The compounds were fully characterized using UV-visible, nuclear magnetic resonance (NMR), infrared (IR) and mass spectrometry. Furthermore, the X-ray polymorphs of a meta-benziporphodimethene analogue were added. The study of its bioimaging applications in MDA-MB-231 breast cancer cells for the detection of Zn2+ ions is reported.